Abstract
Background: Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated.
Methods: We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury (AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrastinduced nephropathy.
Results: Fenoldopam mesylate was found to be effective in reducing the onset of postoperative AKI, when used before the development of the kidney damage. Positive results were also obtained in the management of intensive care unit patients with AKI, although the clinical studies investigated were few and conducted on small samples.
Conclusion: Conflicting results were achieved in contrast-induced nephropathy.
Keywords: Fenoldopam mesylate, post-operative acute kidney injury, contrast-induced nephropathy, Intensive care unit-acute kidney injury, DA-1 receptor, dopamine, chronic kidney disease.
Graphical Abstract
[1]
Murphy, M.B.; Murray, C.; Shorten, G.D. Fenoldopam: A selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N. Engl. J. Med., 2001, 345(21), 1548-1557.
[2]
Weinstock, J.; Wilson, J.W.; Ladd, D.L.; Brush, C.K.; Pfeiffer, F.R.; Kuo, G.Y.; Holden, K.G.; Yim, N.C.; Hahn, R.A.; Wardell, J.R., Jr; Tobia, A.J.; Setler, P.E.; Sarau, H.M.; Ridley, P.T. Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines. J. Med. Chem., 1980, 23(9), 973-975.
[3]
Carey, R.M.; Siragy, H.M.; Ragsdale, N.V.; Howell, N.L.; Felder, R.A.; Peach, M.J.; Chevalier, R.L. Dopamine-1 and dopamine-2 mechanisms in the control of renal function. Am. J. Hypertens., 1990, 3(6 Pt 2), 59S-63S.
[4]
Hughes, J.M.; Beck, T.R.; Rose, C.E., Jr; Carey, R.M. The effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man. J. Clin. Endocrinol. Metab., 1988, 66(3), 518-525.
[5]
Goldberg, L.I. Dopamine receptors and hypertension. Physiologic and pharmacologic implications. Am. J. Med., 1984, 77(4A), 37-44.
[6]
Dohlman, H.G.; Thorner, J.; Caron, M.G.; Lefkowitz, R.J. Model systems for the study of seven-transmembrane-segment receptors. Annu. Rev. Biochem., 1991, 60, 653-688.
[7]
Hahn, R.A.; Wardell, J.R., Jr; Sarau, H.M.; Ridley, P.T. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J. Pharmacol. Exp. Ther., 1982, 223(2), 305-313.
[9]
Bellomo, R.; Chapman, M.; Finfer, S.; Hickling, K.; Myburgh, J. Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet, 2000, 356(9248), 2139-2143.
[10]
Jones, D.; Bellomo, R. Renal-dose dopamine: From hypothesis to paradigm to dogma to myth and, finally, superstition? J. Intensive Care Med., 2005, 20(4), 199-211.
[11]
Kellum, J.A.; Decker, M.J. Use of dopamine in acute renal failure: a meta-analysis. Crit. Care Med., 2001, 29(8), 1526-1531.
[12]
Brogden, R.N.; Markham, A. Fenoldopam: A review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs, 1997, 54(4), 634-650.
[13]
Corlopam- brand of Fenoldopam Mesylate Injection, USP.
www.accessdata.fda.gov/drugsatfda_docs/label/2004/19922se5-005_colopam_lbl.pdf
Accessed November 08,. 2018.
[14]
Lokhandwala, M.F.; Barrett, R.J. Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications. J. Auton. Pharmacol., 1982, 2(3), 189-215.
[15]
Felder, C.C.; Campbell, T.; Albrecht, F.; Jose, P.A. Dopamine inhibits Na(+)-H+ exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am. J. Physiol., 1990, 259(2 Pt 2), F297-F303.
[16]
Mills, K.T.; Xu, Y.; Zhang, W.; Bundy, J.D.; Chen, C.S.; Kelly, T.N.; Chen, J.; He, J. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int., 2015, 88(5), 950-957.
[17]
Aperia, A.; Fryckstedt, J.; Svensson, L.; Hemmings, H.C., Jr; Nairn, A.C.; Greengard, P. Phosphorylated Mr 32,000 dopamine- and cAMP-regulated phosphoprotein inhibits Na+,K(+)-ATPase activity in renal tubule cells. Proc. Natl. Acad. Sci. USA, 1991, 88(7), 2798-27801.
[18]
Brenner, B.M.; Troy, J.L.; Daugharty, T.M.; MacInnes, R.M. Quantitative importance of changes in postglomerular colloid osmotic pressure in mediating glomerulotubular balance in the rat. J. Clin. Invest., 1973, 52(1), 190-197.
[19]
Piltz, J.R.; Stone, R.A.; Boike, S.; Everitt, D.E.; Shusterman, N.H.; Audet, P.; Zariffa, N.; Jorkasky, D.K. Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure. J. Ocul. Pharmacol. Ther., 1998, 14(3), 203-216.
[20]
Makris, K.; Spanou, L. Acute kidney injury: Definition, pathophysiology and clinical phenotypes. Clin. Biochem. Rev., 2016, 37(2), 85-98.
[21]
Rovella, V.; Ferrannini, M.; Tesauro, M.; Marrone, G.; Busca, A.; Sorge, R.; Manca di Villahermosa, S.; Casasco, M.; Di Daniele, N.; Noce, A. Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease. J. Nephrol., 2019, 32(1), 75-81.
[22]
Romagnoli, S.; Ricci, Z. Postoperative acute kidney injury. Minerva Anestesiol., 2015, 81(6), 684-696.
[24]
Pistolesi, V.; Regolisti, G.; Morabito, S.; Gandolfini, I.; Corrado, S.; Piotti, G.; Fiaccadori, E. Contrast medium induced acute kidney injury: a narrative review. J. Nephrol., 2018, 31(6), 797-812.
[25]
Huber, W.; Schneider, J.; Lahmer, T.; Kuchle, C.; Jungwirth, B.; Schmid, R.M.; Schmid, S. Validation of RIFLE, AKIN, and a
modified AKIN definition ("backward classification") of acute kidney
injury in a general ICU: Analysis of a 1-year period. Medicine,
(Baltimore), 2018, 97(38), e12465.
[26]
Gilbert, T.B.; Hasnain, J.U.; Flinn, W.R.; Lilly, M.P.; Benjamin, M.E. Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. J. Cardiovasc. Pharmacol. Ther., 2001, 6(1), 31-36.
[27]
O’Hara, J.F., Jr; Mahboobi, R.; Novak, S.M.; Bonilla, A.M.; Mascha, E.J.; Fergany, A.F.; Campbell, S.C.; Kaouk, J.H.; Kaple, K.M.; Gill, I.S.; Ziegman, S.A.; Sessler, D.I. Fenoldopam and renal function after partial nephrectomy in a solitary kidney: A randomized, blinded trial. Urology, 2013, 81(2), 340-345.
[28]
Ranucci, M.; De Benedetti, D.; Bianchini, C.; Castelvecchio, S.; Ballotta, A.; Frigiola, A.; Menicanti, L. Effects of fenoldopam infusion in complex cardiac surgical operations: A prospective, randomized, double-blind, placebo-controlled study. Minerva Anestesiol., 2010, 76(4), 249-259.
[29]
Biancofiore, G.; Della Rocca, G.; Bindi, L.; Romanelli, A.; Esposito, M.; Meacci, L.; Urbani, L.; Filipponi, F.; Mosca, F. Use of fenoldopam to control renal dysfunction early after liver transplantation. Liver Transpl., 2004, 10(8), 986-992.
[30]
Barr, L.F.; Kolodner, K. N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. Crit. Care Med., 2008, 36(5), 1427-1435.
[31]
Cogliati, A.A.; Vellutini, R.; Nardini, A.; Urovi, S.; Hamdan, M.; Landoni, G.; Guelfi, P. Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: A randomized clinical study. J. Cardiothorac. Vasc. Anesth., 2007, 21(6), 847-850.
[32]
Caimmi, P.P.; Pagani, L.; Micalizzi, E.; Fiume, C.; Guani, S.; Bernardi, M.; Parodi, F.; Cordero, G.; Fregonara, M.; Kapetanakis, E.; Panella, M.; Degasperis, C. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth., 2003, 17(4), 491-494.
[33]
Bove, T.; Landoni, G.; Calabro, M.G.; Aletti, G.; Marino, G.; Cerchierini, E.; Crescenzi, G.; Zangrillo, A. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: A prospective, double-blind, randomized clinical trial. Circulation, 2005, 111(24), 3230-3235.
[34]
Halpenny, M.; Rushe, C.; Breen, P.; Cunningham, A.J.; Boucher-Hayes, D.; Shorten, G.D. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur. J. Anaesthesiol., 2002, 19(1), 32-39.
[35]
Halpenny, M.; Lakshmi, S.; O’Donnell, A.; O’Callaghan-Enright, S.; Shorten, G.D. Fenoldopam: Renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia, 2001, 56(10), 953-960.
[36]
Oliver, W.C., Jr; Nuttall, G.A.; Cherry, K.J.; Decker, P.A.; Bower, T.; Ereth, M.H. A comparison of fenoldopam with dopamine and sodium nitroprusside in patients undergoing cross-clamping of the abdominal aorta. Anesth. Analg., 2006, 103(4), 833-840.
[37]
Della Rocca, G.; Pompei, L.; Costa, M.G.; Coccia, C.; Scudeller, L.; Di Marco, P.; Monaco, S.; Pietropaoli, P. Fenoldopam mesylate and renal function in patients undergoing liver transplantation: a randomized, controlled pilot trial. Anesth. Analg., 2004, 99(6), 1604-1609. table of contents.
[38]
McCune, T.R.; Wombolt, D.G.; Whelan, T.V.; Thacker, L.R.; Colonna, J.O. Vasodilatation vs. immunotherapy to prevent delayed graft function: Delayed graft function as an indication of immune activation. Int. Immunopharmacol., 2005, 5(1), 85-92.
[39]
Roasio, A.; Lobreglio, R.; Santin, A.; Landoni, G.; Verdecchia, C. Fenoldopam reduces the incidence of renal replacement therapy after cardiac surgery. J. Cardiothorac. Vasc. Anesth., 2008, 22(1), 23-26.
[40]
Ranucci, M.; Soro, G.; Barzaghi, N.; Locatelli, A.; Giordano, G.; Vavassori, A.; Manzato, A.; Melchiorri, C.; Bove, T.; Juliano, G.; Uslenghi, M.F. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann. Thorac. Surg., 2004, 78(4), 1332-1337. discussion 1337-1338
[41]
Zangrillo, A.; Biondi-Zoccai, G.G.; Frati, E.; Covello, R.D.; Cabrini, L.; Guarracino, F.; Ruggeri, L.; Bove, T.; Bignami, E.; Landoni, G. Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials. J. Cardiothorac. Vasc. Anesth., 2012, 26(3), 407-413.
[42]
Gillies, M.A.; Kakar, V.; Parker, R.J.; Honore, P.M.; Ostermann, M. Fenoldopam to prevent acute kidney injury after major surgerya systematic review and meta-analysis. Crit. Care, 2015, 19, 449.
[43]
Bove, T.; Zangrillo, A.; Guarracino, F.; Alvaro, G.; Persi, B.; Maglioni, E.; Galdieri, N.; Comis, M.; Caramelli, F.; Pasero, D.C.; Pala, G.; Renzini, M.; Conte, M.; Paternoster, G.; Martinez, B.; Pinelli, F.; Frontini, M.; Zucchetti, M.C.; Pappalardo, F.; Amantea, B.; Camata, A.; Pisano, A.; Verdecchia, C.; Dal Checco, E.; Cariello, C.; Faita, L.; Baldassarri, R.; Scandroglio, A.M.; Saleh, O.; Lembo, R.; Calabro, M.G.; Bellomo, R.; Landoni, G. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: A randomized clinical trial. JAMA, 2014, 312(21), 2244-2253.
[44]
Bakris, G.L.; Lass, N.A.; Glock, D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int., 1999, 56(1), 206-210.
[45]
Kini, A.S.; Mitre, C.A.; Kim, M.; Kamran, M.; Reich, D.; Sharma, S.K. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: Effect of selective dopamine receptor agonist fenoldopam. Catheter. Cardiovasc. Interv., 2002, 55(2), 169-173.
[46]
Kini, A.S.; Mitre, C.A.; Kamran, M.; Suleman, J.; Kim, M.; Duffy, M.E.; Marmur, J.D.; Sharma, S.K. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am. J. Cardiol., 2002, 89(8), 999-1002.
[47]
Madyoon, H.; Croushore, L.; Weaver, D.; Mathur, V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter. Cardiovasc. Interv., 2001, 53(3), 341-345.
[48]
Tumlin, J.A.; Wang, A.; Murray, P.T.; Mathur, V.S. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy. Am. Heart J., 2002, 143(5), 894-903.
[49]
Allaqaband, S.; Tumuluri, R.; Malik, A.M.; Gupta, A.; Volkert, P.; Shalev, Y.; Bajwa, T.K. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter. Cardiovasc. Interv., 2002, 57(3), 279-283.
[50]
Stone, G.W.; McCullough, P.A.; Tumlin, J.A.; Lepor, N.E.; Madyoon, H.; Murray, P.; Wang, A.; Chu, A.A.; Schaer, G.L.; Stevens, M.; Wilensky, R.L.; O’Neill, W.W.; Investigators, C. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA, 2003, 290(17), 2284-2291.
[51]
Ng, T.M.; Shurmur, S.W.; Silver, M.; Nissen, L.R.; O’Leary, E.L.; Rigmaiden, R.S.; Cieciorka, M.; Porter, L.L.; Ineck, B.A.; Kline, M.E.; Puumala, S.E. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN). Int. J. Cardiol., 2006, 109(3), 322-328.
[52]
Briguori, C.; Colombo, A.; Airoldi, F.; Violante, A.; Castelli, A.; Balestrieri, P.; Paolo Elia, P.; Golia, B.; Lepore, S.; Riviezzo, G.; Scarpato, P.; Librera, M.; Focaccio, A.; Ricciardelli, B. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol., 2004, 44(4), 762-765.
[53]
Kelly, A.M.; Dwamena, B.; Cronin, P.; Bernstein, S.J.; Carlos, R.C. Meta-analysis: Effectiveness of drugs for preventing contrast-induced nephropathy. Ann. Intern. Med., 2008, 148(4), 284-294.
[54]
Naeem, M.; McEnteggart, G.E.; Murphy, T.P.; Prince, E.; Ahn, S.; Soares, G. Fenoldopam for the prevention of contrast-induced nephropathy (CIN)-do we need more trials? A meta-analysis. Clin. Imaging, 2015, 39(5), 759-764.
[55]
Su, X.; Xie, X.; Liu, L.; Lv, J.; Song, F.; Perkovic, V.; Zhang, H. Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: A systematic review and bayesian network meta-analysis. Am. J. Kidney Dis., 2017, 69(1), 69-77.
[56]
Mathur, V.S.; Swan, S.K.; Lambrecht, L.J.; Anjum, S.; Fellmann, J.; McGuire, D.; Epstein, M.; Luther, R.R. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit. Care Med., 1999, 27(9), 1832-1837.
[57]
Drager, L.F.; Andrade, L.; Barros de Toledo, J.F.; Laurindo, F.R.; Machado Cesar, L.A.; Seguro, A.C. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol. Dial. Transplant., 2004, 19(7), 1803-1807.
[58]
Brienza, N.; Malcangi, V.; Dalfino, L.; Trerotoli, P.; Guagliardi, C.; Bortone, D.; Faconda, G.; Ribezzi, M.; Ancona, G.; Bruno, F.; Fiore, T. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit. Care Med., 2006, 34(3), 707-714.
[59]
Morelli, A.; Ricci, Z.; Bellomo, R.; Ronco, C.; Rocco, M.; Conti, G.; De Gaetano, A.; Picchini, U.; Orecchioni, A.; Portieri, M.; Coluzzi, F.; Porzi, P.; Serio, P.; Bruno, A.; Pietropaoli, P. Prophylactic fenoldopam for renal protection in sepsis: A randomized, double-blind, placebo-controlled pilot trial. Crit. Care Med., 2005, 33(11), 2451-2456.
[60]
Tumlin, J.A.; Finkel, K.W.; Murray, P.T.; Samuels, J.; Cotsonis, G.; Shaw, A.D. Fenoldopam mesylate in early acute tubular necrosis: A randomized, double-blind, placebo-controlled clinical trial. Am. J. Kidney Dis., 2005, 46(1), 26-34.
[61]
Cobas, M.; Paparcuri, G.; De La Pena, M.; Cudemus, G.; Barquist, E.; Varon, A. Fenoldopam in critically ill patients with early renal dysfunction. A crossover study. Cardiovasc. Ther., 2011, 29(4), 280-284.
[62]
Landoni, G.; Biondi-Zoccai, G.G.; Tumlin, J.A.; Bove, T.; De Luca, M.; Calabro, M.G.; Ranucci, M.; Zangrillo, A. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: A meta-analysis of randomized clinical trials. Am. J. Kidney Dis., 2007, 49(1), 56-68.
Related Books
Industrial Applications of Soil Microbes
Industrial Applications of Soil Microbes
Algal Biotechnology for Fuel Applications
Biopolymers Towards Green and Sustainable Development
Terpenoids: Recent Advances in Extraction, Biochemistry and Biotechnology
Environmental Microbiology: Advanced Research and Multidisciplinary Applications
Biomarkers in Medicine
Industrial Applications of Soil Microbes
Recent Advances in Biotechnology
Sustainable Utilization of Fungi in Agriculture and Industry
Article Metrics
35
5
2
1